Data investigation

Many People Never Reach the Dose

Only 58% of people starting semaglutide reached the recommended maintenance dose after four weeks, and 21% stayed on the starting dose. More than half of oral semaglutide starters stopped altogether.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

There is a simple explanation for why real-world results look worse than trial results, and it is not that patients are different. A UK population study found that only 58% of people starting semaglutide reached the recommended maintenance dose after four weeks, and 21% were still on the starting dose, the one that exists to be tolerated rather than to work.[1]

Where people end up

By the tenth prescription, the commonest subcutaneous semaglutide doses were 0.5 mg (44.0%) and 1 mg (48.6%). The 2 mg dose was not prescribed in this database during the study period, so 1 mg was the top of the ladder these patients were on.[1] Nearly half were still a step below it after ten prescriptions, which is most of a year.

Escalation was faster in people with higher BMI, and the authors found no further variation by other patient characteristics, including established cardiovascular disease. Delayed escalation was, in their words, frequent across all patient stratifications.[1] The ladders themselves differ in length: Saxenda’s dose ladder is the shortest climb to a full dose among the GLP‑1 weight drugs, 0.6 mg a day raised by 0.6 mg each week to 3.0 mg in week five, where the others take months to reach their top dose.

A trial escalates on protocol. Ordinary care escalates when someone remembers to.

And half of them stop

Discontinuation rates in UK primary care, by drug and formulation.
DrugDiscontinued
Dulaglutide36.9%
Semaglutide, subcutaneous46.4%
Semaglutide, oral55.8%

More than half of the people who started the oral version stopped.[1] That is the formulation sold on convenience, yet it has the strictest daily conditions: an empty stomach on waking, then a wait before anything else (see travel and time zones). A convenient format does not make for a convenient routine.

The worst nausea in our side-effect ranking belonged to another oral drug, orforglipron. That says nothing directly about oral semaglutide.

Why this reframes so much else

We wrote recently that real-world data shows outcome differences by race and ethnicity where randomized trials showed none, and argued the gap lies in access, continuity and titration rather than in patients (see who responds in the real world). This study puts numbers on the titration half of that argument.

If a fifth of people are still on the starting dose when the first step up is due and nearly half stop altogether, then a large part of “the drug worked less well than in trials” is really “the drug was never taken at the dose it was tested at, for the duration it was tested for”. Those are different problems with different solutions. Stopping itself splits the same way: not tolerating a drug and not taking it reliably have different predictors.

This is also why plateau advice so often misses. Someone whose weight loss has stalled at a low dose is not a non-responder; they may simply be under-dosed. That is a conversation about titration with a prescriber, and it is a much more likely explanation than needing a different drug. Our article on switching covers why changing drugs restarts the ladder rather than skipping it.

What this does not establish

  • It is a type 2 diabetes population in UK primary care. Dosing targets, prescribing incentives and follow-up patterns differ from US weight-management practice.
  • It does not say why people stopped. Side effects, cost, supply and simply not returning are all in there, undifferentiated.
  • Slow escalation is sometimes correct. Holding a dose because someone is nauseated is good medicine, not a failure, and the labels build that judgment in.
  • Higher is not automatically better. For tirzepatide the step from 10 to 15 mg added little on average, as which Zepbound dose works best shows. The point is that most people never get the chance to find out.

Frequently Asked Questions

In part because many people never reach the dose. In a UK population study, only 58% of semaglutide initiators reached recommended maintenance doses after four weeks and 21% remained on the starting dose. Trials escalate on protocol; ordinary care frequently does not.
In this cohort, 36.9% discontinued dulaglutide, 46.4% subcutaneous semaglutide and 55.8% oral semaglutide. More than half of the people who started the oral version stopped.
The study does not say, but the oral formulation has the strictest daily conditions. It is taken on waking on an empty stomach, with a wait before food or other tablets. The format is more convenient than an injection; the routine around it is not.
It is a much more likely explanation than most people assume. Raise it with a prescriber before concluding the drug does not work for you. Someone stalled at a starting dose is not a non-responder.
No. Holding a dose because someone cannot tolerate the next step is good medicine, and every label builds that judgment in. The finding is that delayed escalation was frequent across all groups, not that any individual decision was wrong.

References

  1. 1.Ulrich FS, Napoli N, Nielsen MF, et al. Real-world persistence and dose titration of GLP-1 receptor agonists in type 2 diabetes: A UK population-based cohort study Diabetes, Obesity and Metabolism. 2026. PMID: 41703773.

Why Combination Therapy Fails in Practice

A pragmatic trial of combining two diabetes drugs found 53% filled the prescription against 84% on one drug, and half of those who filled later stopped one. The participants were insured.

5 min read

Every Other Week: Stretching the Interval

Patients moved to every-other-week dosing after a plateau held their weight and body composition over 36 weeks. It is a case series with no control group, and it is the third of three different ways to use less drug.

5 min read

Switching Between GLP-1 Drugs

No label contains a dose equivalence between semaglutide and tirzepatide, because no regulator has been asked to approve one. Every conversion chart online is somebody's arithmetic.

5 min read

A Pill to Hold What the Injection Lost

Daily oral orforglipron maintained 79.3% of weight already lost against 37.6% on placebo at a year in people coming off semaglutide, and 74.7% against 49.2% after tirzepatide. The trial had no arm that stayed on the injection, which is the question people actually have.

5 min read

GLP-1s, Travel and Time Zones

For a weekly injection, time zones barely matter: a week is 168 hours and an eight-hour shift is under 5% of it. The daily oral, anchored to waking rather than the clock, is the one that needs planning.

5 min read

BPC-157 Dosage: What the Human Studies Actually Gave

There is no approved BPC-157 dose. The five published human studies used enemas, knee or bladder injections and IV infusions, never the subcutaneous, oral or topical routes sold. Why rat µg/kg doses and dosage charts do not convert.

9 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

MyDrHank

An oral route if you will not self-inject

9.0

YourEra

Semaglutide at $99/month, well below the typical price

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →